Bank of Nova Scotia Raises Stock Position in Bristol Myers Squibb Company $BMY

Bank of Nova Scotia grew its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY) by 41.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 755,568 shares of the biopharmaceutical company’s stock after buying an additional 223,196 shares during the quarter. Bank of Nova Scotia’s holdings in Bristol Myers Squibb were worth $34,076,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the business. Darwin Wealth Management LLC purchased a new stake in shares of Bristol Myers Squibb in the second quarter valued at $25,000. Harbor Capital Advisors Inc. boosted its stake in shares of Bristol Myers Squibb by 107.2% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 313 shares during the period. Total Investment Management Inc. bought a new position in Bristol Myers Squibb during the 2nd quarter valued at about $38,000. Twin Peaks Wealth Advisors LLC purchased a new stake in Bristol Myers Squibb in the 2nd quarter worth about $40,000. Finally, Bank of Jackson Hole Trust lifted its stake in Bristol Myers Squibb by 352.2% in the third quarter. Bank of Jackson Hole Trust now owns 1,040 shares of the biopharmaceutical company’s stock worth $47,000 after purchasing an additional 810 shares during the last quarter. Institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Price Performance

Shares of NYSE BMY opened at $59.73 on Tuesday. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $62.89. The company has a market cap of $121.63 billion, a PE ratio of 17.31, a P/E/G ratio of 0.17 and a beta of 0.26. The company has a debt-to-equity ratio of 2.32, a quick ratio of 1.14 and a current ratio of 1.26. The business has a 50-day simple moving average of $58.37 and a two-hundred day simple moving average of $51.55.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.65 by ($0.39). The company had revenue of $12.50 billion for the quarter, compared to analyst estimates of $12.24 billion. Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The business’s revenue was up 1.3% compared to the same quarter last year. During the same quarter last year, the company earned $1.67 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, equities analysts expect that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, May 1st. Shareholders of record on Thursday, April 2nd will be issued a $0.63 dividend. The ex-dividend date of this dividend is Thursday, April 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.2%. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 73.04%.

Wall Street Analyst Weigh In

A number of research firms have recently commented on BMY. HSBC reaffirmed a “hold” rating and set a $53.00 target price on shares of Bristol Myers Squibb in a research note on Wednesday, December 10th. Wells Fargo & Company restated an “outperform” rating and set a $60.00 price objective (up from $55.00) on shares of Bristol Myers Squibb in a report on Friday, February 6th. Scotiabank reiterated a “sector perform” rating and issued a $60.00 target price (up from $53.00) on shares of Bristol Myers Squibb in a research note on Friday, January 9th. Royal Bank Of Canada began coverage on Bristol Myers Squibb in a research report on Tuesday, February 24th. They set a “sector perform” rating and a $60.00 target price for the company. Finally, UBS Group reissued a “buy” rating and set a $70.00 target price on shares of Bristol Myers Squibb in a research note on Friday, March 6th. Nine research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Bristol Myers Squibb has an average rating of “Hold” and a consensus price target of $61.00.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.